Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Friday, May, 5th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.22) by $0.03. The business had revenue of $19 million for the quarter, compared to analysts' expectations of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm's revenue for the quarter was up 160.3% on a year-over-year basis. During the same quarter last year, the company earned ($1.21) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Alnylam Pharmaceuticals.

17 equities research analysts have issued 1 year price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $36.00 to $131.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $80.12 in the next year. View Analyst Ratings for Alnylam Pharmaceuticals.

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)
• 2. Needham & Company LLC analysts commented, "Alnylam reported additional results from Phase 2 OLE trial of fitusiran in Hemophilia A and B pts w/ and w/ o inhibitors. Efficacy w/ respect to Annualized Bleeding Rate and target antithrombin knockdown remains favorable and consistent w/ prior data from this program. Alnylam reported several asymptomatic >3X ALT elevations, one of which led to a discontinuation. Mgmt believes these events may be tied to HCV infection, highlighting that all events occurred in pts w/ history of HCV and most significant events were observed in pts w/ active infection. Alnylam is excluding Hemophilia pts w/ active HCV infection from Phase 3 trials. Data from Phase 1 trial published today are not consistent with a dose-dependent impact on ALT elevation. We continue to have a favorable view towards the program given current overall profile (safety, efficacy, and convenience), but acknowledge a level of risk around liver enzymes, which will probably not be clarified until Phase 3 completed." (7/10/2017)
• 3. Chardan Capital analysts commented, "We now seen Alnylam as the leader in the clinical HBV RNAi therapy space. As discussed in our 14 October 2016 company note for Arbutus (Buy), we believe ARB-1467 has demonstrated at best mediocre phase IIa results that were predictable based on inferior preclinical data relative to Alnylam’s RNAi asset, ALN-HBV . Additionally, ALN-HBV has a favorable dosing route in subcutaneous delivery compared to Arbutus’ ARB-1467 and ARB-1740, which are administered by intravenous injection. With Arrowhead moving to preclinical development in HBV , we now view Alnylam as the leader in the space." (11/30/2016)

Some companies that are related to Alnylam Pharmaceuticals include Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Exact Sciences Corporation (EXAS), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE) and INC Research Holdings (INCR).

Alnylam Pharmaceuticals' management team includes the folowing people:

• Michael W. Bonney, Independent Chairman of the Board
• Barry E. Greene, President
• John M. Maraganore Ph.D., Chief Executive Officer, Director
• Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer
• Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President
• Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development
• Laurie B. Keating, Senior Vice President, General Counsel, Secretary
• Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
• Theresa Heggie, Senior Vice President, Head of Europe and Canada
• Peter F. Smith Ph.D., Senior Vice President - Early Development

Alnylam Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Rockefeller Financial Services Inc. (0.39%), Peregrine Capital Management LLC (0.23%), Aperio Group LLC (0.02%), Bank of Montreal Can (0.01%), Nisa Investment Advisors LLC (0.01%) and NN Investment Partners Holdings N.V. (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Rockefeller Financial Services Inc., Peregrine Capital Management LLC and Winslow Evans & Crocker Inc.. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Hemenway Trust Co LLC, Capstone Asset Management Co., Nisa Investment Advisors LLC, Aperio Group LLC and Bank of Montreal Can. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $82.02.